Atem Capital: Arpeggio Biosciences Raises $17M in Series A Funding

Arpeggio Biosciences, a Boulder, CO-based preclinical therapeutics company whose technology targets transcriptional dysregulation in disease, raised $17m in Series A funding. The round, which follows a $3.2m seed round completed in 2020, was led by Builders VC with participation from Khosla Ventures, TechU Ventures, FundersClub, Alice Zhang, and Fifty Years, with new participation from Tencent, [...]The post Arpeggio Biosciences Raises $17M in Series A Funding appeared first on FinSMEs.